Skip to main content
MBAI logo

MBody AI Ltd. (MBAI) Stock: Price, Forecast & Analyst Target

MBody AI Ltd. (MBAI) — MoonshotScore 61/100 (Fair band), calculated Oct 4, 2026. Price $3.29 (+4.11%), as of the Oct 2, 2026 trading session; market cap $3.30M.

Educational signal · not a buy or sell recommendation · How to read this

$3.29 +$0.13 (+4.11%) Market Cap $3.30M

MBody AI Ltd. · MBAI · NASDAQ

Check-Cap Ltd. is a clinical-stage medical diagnostics company specializing in capsule-based screening technology. Their primary focus is on developing a non-invasive alternative for colorectal cancer screening.

Price as of Oct 2, 2026

Key Statistics

61 of 100

MoonshotScore v2 · MBody AI (MBAI)

Fair
Business Quality Solid (72)
Financial Safety Okay (45)
Valuation Cheap (86)
Growth Durability Compounding (94)
Momentum Falling (13)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and elite growth, at a cheap price, though the balance sheet is only middling, and the price trend has turned against it. Business Quality: Solid; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Falling.

  • EPS beat 3 of 5
  • ROE 416.7% · ROA 55.3% · current ratio 0.05 · earnings yield 72.7% · free-cash-flow yield -0.7%

Holding back: weak price trend

Helping: business quality, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MBAI (29 recorded, newest six shown)
RecordedScoreBand
62Fair
62Fair
61Fair
61Fair
61Fair
61Fair

The score moved from 57 in the stored Oct 3, 2026 snapshot to 61 in the current publication computed Oct 4, 2026 (+4); the largest pillar moves were Momentum -1.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.29
Change on the day+4.11%
52-week range$3.33 – $27.44
Market capitalisation$3.30M
Price / earnings (trailing)0.71
Shares traded on the day12.3K

Price & events

Other perspectives

Council score for MBody AI (MBAI): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Weak
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Neutral
Insider Activity Moderate
Trading Liquidity Strong
Price Momentum Moderate
News Sentiment Neutral

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the MBAI film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is MBody AI (MBAI), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. MBody AI Ltd. (MBAI) is listed on NASDAQ. It employs 85 people and is led by John Fowler. The market values it at $3.30M.

2 · Latest results

What do the latest results show for MBody AI (MBAI)?

Short answer · as of

Against analyst estimates the company has EPS beat 3 of 5 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for MBody AI (MBAI)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. What is holding it back is weak price trend. Trailing ratios: ROE 416.7% · ROA 55.3% · current ratio 0.05 · earnings yield 72.7% · free-cash-flow yield -0.7%.

4 · What to check next?

What should you watch next at MBody AI (MBAI)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $4.76M · EPS -0.02 · 1 analysts. Current published price targets run low $10.00 · high $10.00 · consensus $10.00 · median $10.00 against a quoted price of $3.29 (as of Oct 2, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for MBAI.
  • No Altman Z or Piotroski screen is held for this filer.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does MBody AI compare with its peers?

Short answer

MBody AI's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
CorMedix Inc. (CRMD) Same industry, near in market value$7.19 Oct 2, 2026$564M94 5-pillar Oct 4, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$47.15 Oct 2, 2026$872M93 5-pillar Oct 4, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.99 Oct 2, 2026$591M91 5-pillar Oct 4, 2026
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.59 Oct 2, 2026$669M88 5-pillar Oct 4, 2026
Arbutus Biopharma Corporation (ABUS) Same industry, near in market value$4.45 Oct 2, 2026$879M85 5-pillar Oct 4, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$17.08 Oct 2, 2026$90.6M83 5-pillar Oct 4, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$9.75 Oct 2, 2026$88.2M79 5-pillar Oct 4, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$9.75 Oct 2, 2026$690M77 5-pillar Oct 4, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.49 Oct 2, 2026$184M76 5-pillar Oct 4, 2026
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.79 Oct 2, 2026$222M69 5-pillar Oct 4, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$10.94 Oct 2, 2026$626M68 5-pillar Oct 4, 2026
AN2 Therapeutics, Inc. (ANTX) Same industry, near in market value$5.71 Oct 2, 2026$206M67 5-pillar Oct 4, 2026
MBody AI (MBAI) — this page$3.29$3.30M61

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$10.00 – $10.00
Consensus target
$10.00
Median target
$10.00
Revenue estimate
$4.76M
EPS estimate
$-0.02

Consensus record · Captured .

Measured against a quoted price of $3.29 (as of Oct 2, 2026).

What has been published about MBody AI (MBAI)?

Read these with our analysis →

MBody AI Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the MBAI research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MBAI?

MBAI carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Check-Cap Ltd. is a clinical-stage medical diagnostics company specializing in capsule-based screening technology.

Is MBAI a good stock to buy?

Stock Expert AI does not rate MBAI buy, sell or hold. MBody AI Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MBAI stock price today?

The last price recorded on this page for MBody AI Ltd. (MBAI) is $3.29, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MBAI price target?

The analyst consensus price target for MBody AI Ltd. (MBAI) is $10.00 (range $10.00 to $10.00, median $10.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What is Check-Cap Ltd. Ordinary Share's drug pipeline status?

Check-Cap Ltd. Ordinary Share does not have a traditional drug pipeline. Instead, its primary focus is on the development and commercialization of the C-Scan system, a capsule-based device for colorectal cancer screening.

What are the key factors to evaluate for MBAI?

MBody AI Ltd. (MBAI) holds a MoonshotScore in the moderate range. P/E: 0.71x. Analysts target $10.00 (+204%). David Lontini serves as the CEO, leading the company's strategic direction. Not financial advice.

How frequently does MBAI data refresh on this page?

MBAI's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MBAI's recent stock price performance?

MBody AI Ltd. (MBAI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative capsule-based screening technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MBAI overvalued or undervalued right now?

MBody AI Ltd. (MBAI) trades at 0.71x earnings. Analysts target $10.00 (+204%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (20 figures)

The 20 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 10 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$3.29FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T20:54:47.945Z.
px.changeChange on the day+4.11%FMPFinancial Modeling Prep (FMP) · quote
px.mcapMarket capitalisation$3.30MFMPFinancial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T20:54:46.956Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares.
px.change_absChange on the day, in dollars+$0.13FMPFinancial Modeling Prep (FMP) · quote
px.pePrice / earnings (trailing)0.71FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day12.3KFMPFinancial Modeling Prep (FMP) · quote
earn.ptStored analyst price targetslow $10.00 · high $10.00 · consensus $10.00 · median $10.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_rangeAnalyst price target, low to high$10.00 – $10.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_consensusConsensus analyst price target$10.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied
earn.pt_medianMedian analyst price target$10.00FMPFinancial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied

UNRECORDED — 8 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
earn.historyReported versus estimated, recent quartersEPS beat 3 of 5UNRECORDEDStored earnings-history observation — Captured 2026-10-01 · Expired observation
fin.ratiosReturn and yield ratios (trailing twelve months)ROE 416.7% · ROA 55.3% · current ratio 0.05 · earnings yield 72.7% · free-cash-flow yield -0.7%—UNRECORDEDStored key metrics — Date unknown
px.range5252-week range$3.33 – $27.44UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.employeesEmployees85UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.ceoChief executiveJohn FowlerUNRECORDEDStored company-profile observation — Captured 2026-10-01
earn.estimatesAnalyst estimates, next fiscal yearFY2026 revenue $4.76M · EPS -0.02 · 1 analystsUNRECORDEDStored analyst estimates — Captured 2026-09-30 · Expired observation
earn.est_revenueRevenue estimate, FY2026$4.76MUNRECORDEDStored analyst estimates — Captured 2026-09-30 · Expired observation
earn.est_epsEPS estimate, FY2026$-0.02UNRECORDEDStored analyst estimates — Captured 2026-09-30 · Expired observation

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v261 of 100 · Fair · pillars 72 / 45 / 86 / 94 / 13OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement57 (stored snapshot Oct 3, 2026) → 61 (current publication computed Oct 4, 2026) (+4)OURSStock Expert AI current score publication and immutable score snapshots
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.